ModifiedUnitedHealthcarePolicy CS132NE.Q

Noncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (for Nebraska Only)

This policy governs coverage and medical necessity determinations for noncontact normothermic wound warming (NNWT), low-frequency (noncontact and contact) ultrasound therapies (including MIST/MIST Therapy®/NLFU) and real-time fluorescence wound imaging for bacterial detection in Nebraska members.

Policy Summary

PayerUnitedHealthcare

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (for Nebraska Only)

Policy CodePolicy CS132NE.Q

Change TypeAnnual coding update

Effective DateMar 1, 2026

Next Review DateN/A

Key ActionWhen submitting claims, document procedure code(s), clinical rationale, and link use of imaging or devices to standard care and management decisions; check updated CPT descriptions for 0598T and 0599T and confirm any prior authorization requirements.

SourceLink

POLICY UPDATE CHANGES

Updated list of applicable CPT codes to reflect annual edits; revised description for 0598T and 0599T.

Updated list of applicable CPT codes to reflect annual edits and revised description for 0598T and 0599T.

3interventions evaluated

Nebraskastate application

Insufficientcoverage rationale

Several

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

337large RCT participants

Updatedapplicable codes edited

Coverage Determinations

inv-01: Warming therapy — coverage stance

Covered when ALL of the following are met:

Warming therapy (NNWT): Warming therapy or noncontact normothermic wound therapy (NNWT) is considered not medically necessary due to insufficient evidence of efficacy for treating wounds.

Policy conclusion based on evidence summarized in the coverage rationale and service description (see chunks 3 and 5).

inv-02: Low-frequency ultrasound — coverage stance

Low-frequency ultrasound therapy (contact and noncontact, e.g., MIST Therapy®/NCLF-US) is considered not medically necessary due to insufficient and mixed evidence; existing randomized trials and systematic reviews report small samples, methodological limitations, and no consistent benefit for patient-centered outcomes.

Key trials include small pilot RCTs showing possible benefit with increased frequency (chunk 19) and a large RCT showing no benefit and more adverse events with weekly therapy (chunk 20).

inv-03: Fluorescence imaging — coverage stance

Real-time fluorescence wound imaging: Noncontact real-time fluorescence wound imaging for bacterial presence (e.g., MolecuLight i:X®) is considered not medically necessary due to insufficient evidence that use of the device improves patient-centered outcomes.

Diagnostic accuracy and detection of bacterial loads have been reported, but clinical utility for improved healing or recurrence has not been established (see chunks 5 and 37).

inv-04: Coverage considerations for ultrasound and fluorescence imaging

Coverage considerations based on available evidence:

Low-dose/high-frequency therapeutic ultrasound: Randomized evidence is mixed: a large RCT (n=337) found no improvement in time to healing or quality of life and reported more adverse events with weekly low-dose high-frequency ultrasound plus standard care versus standard care alone; smaller randomized/pilot trials reported shorter mean healing times or improved percent area reduction when ultrasound was applied more frequently (e.g., thrice weekly), but these findings are limited by small sample sizes, lack of masking, and risk of bias.

Clinical utility not established; further large, well-designed trials are needed (chunks 18, 19, 20).

Noncontact fluorescence wound imaging (e.g., MolecuLight i:X): Diagnostic studies demonstrate increased sensitivity and accuracy for detecting moderate-to-heavy bacterial loads compared with clinical signs alone and may identify areas at risk (e.g., for graft failure). However, evidence is inconclusive that device use leads to improved patient-centered outcomes (healing, recurrence), and additional randomized controlled trials are required.detects bacteria ≥10^4 CFU/g (device detection limit); laboratory culture thresholds often use ≥10^5 CFU/g

May be a useful adjunct to clinical assessment for targeting debridement or sampling but lacks conclusive outcome data (chunk 37, 41, 42).

inv-05: DFU-specific adjunctive evidence

Adjunctive use in diabetic foot ulcers (DFU):

NCLF-US for DFU (pilot evidence): Small randomized pilot data suggest noncontact low-frequency ultrasound applied three times per week may produce greater percent area reduction in DFU compared with less frequent or no ultrasound, but sample sizes are small and results require confirmation in larger trials.

Example: Yao et al. pilot (12 DFUs) reported greatest PAR (86%) with thrice-weekly NCLF-US; authors recommend larger trials (chunk 19).

Fluorescence-guided management for DFU: A pilot RCT of autofluorescence-informed DFU management showed a higher proportion healed at 12 weeks in the imaging-informed arm versus control, with favorable wound area reduction trends, but the study was underpowered and requires confirmation in fully powered RCTs.

Rahma et al. pilot RCT (n=56) reported 45% vs 22% healed at 12 weeks favoring autofluorescence-informed care but was not powered for definitive conclusions (chunk 34).

inv-06: Adjunctive device use

Coverage considerations reflect limited and inconclusive evidence; adjunctive device use should align with guideline-recommended standard care and multidisciplinary advice.

General coverage conditions for adjunctive noncontact wound devices: Device or adjunctive therapy may be considered only when ALL of the following are documented: 1) standard wound care appropriate to the wound type has been applied (e.g., offloading for DFU, compression for venous ulcers, debridement, ischemia and infection control, appropriate dressings); 2) healing has not progressed as expected despite standard care; 3) use is on the advice of or in consultation with a multidisciplinary service where recommended; 4) documentation includes clinical assessment, rationale for device use, and how device findings will inform management decisions.

Aligned with NICE and AAWC guidance recommending adjunctive use only after standard measures and multidisciplinary input (chunks 43, 46, 37).

inv-07: Bacterial fluorescence imaging

Use of point-of-care fluorescence bacterial imaging may be considered for detection of moderate-to-heavy bacterial loads when combined with clinical assessment and used to guide targeted debridement or sampling.

Fluorescence imaging (MolecuLight i:X) use criteria: Covered when ALL: 1) a documented clinical signs and symptoms (CSS) assessment is recorded (e.g., IWII checklist or NERDS/STONEES); 2) fluorescence imaging findings are documented and correlated with the clinical assessment; 3) fluorescence-guided actions are taken and documented (targeted swab, targeted debridement, topical or systemic antimicrobial decision); 4) the provider documents that imaging findings will inform, not solely determine, management decisions and that follow-up/confirmation (e.g., culture or clinical reassessment) will occur as indicated.

Reflects evidence that fluorescence imaging increases detection sensitivity for bacterial loads ≥10^4 CFU/g but lacks definitive outcome data; imaging should augment clinical assessment (chunks 37, 41, 42).

No positive coverage criteria are provided for noncontact normothermic wound warming (NNWT), low-frequency ultrasound therapy, or noncontact real-time fluorescence wound imaging. These therapies are described in the policy as unproven and not medically necessary for treating wounds due to insufficient evidence of efficacy.

An independent clinical evidence assessment (ECRI) found the evidence for the MolecuLight i:X fluorescence imaging system to be inconclusive; studies to date do not demonstrate improvement in patient-centered outcomes and additional randomized trials are needed. While the device may increase detection sensitivity for elevated bacterial loads, this diagnostic accuracy has not been shown to translate consistently into improved healing or other clinical outcomes.

The policy does not support replacing established standard-of-care treatments (for example, offloading, debridement, ischemia control, infection control, and appropriate dressings) with these adjunctive technologies as first-line therapy. Guideline sources (NICE) and the policy note that existing evidence does not support routine adoption of these devices in place of standard care.

This Medical Policy is provided for informational purposes and does not constitute medical advice. Coverage determinations must reference the federal, state, or contractual requirements specific to the benefit plan; in the event of a conflict, those requirements govern.

Warming therapy (NNWT), low-frequency ultrasound therapy (contact and noncontact), and noncontact real-time fluorescence wound imaging for bacterial presence are considered not medically necessary based on currently available evidence indicating insufficient demonstration of efficacy and/or safety.

A large randomized controlled trial evaluating weekly low-dose, high-frequency therapeutic ultrasound plus standard care for hard-to-heal venous leg ulcers (n = 337) found no improvement in time to healing, no quality-of-life benefit, and more adverse events compared with standard care alone. Based on this trial, weekly administration of this ultrasound regimen did not increase ulcer healing rates and is therefore considered not supported by the evidence.

Routine use of MolecuLight i:X or similar fluorescence imaging without correlation to clinical assessment and without evidence that imaging-guided actions improve patient outcomes is considered not medically necessary. Documentation relying solely on device findings, absent linkage to management decisions and outcome benefit, is insufficient to establish medical necessity.

Coding and Billing

Referenced CPT/HCPCS Codesmixed

0598T	Real-time fluorescence wound imaging with clinical darkness, to identify location of bacterial wound pathogens and measure wound size, per session; first anatomic site (e.g., lower extremity, right leg).
0599T	Real-time fluorescence wound imaging with clinical darkness, to identify location of bacterial wound pathogens and measure wound size, per session; each additional anatomic site (e.g., upper extremity, left leg) (List separately in addition to code for primary procedure).
97610	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day

Bacterial load detection threshold — fluorescence device vs lab culture

Device detection limitFluorescence imaging devices detect bacterial fluorescence beginning at approximately 1 x 10^4 CFU/g (≈10^4 CFU/g).

Microbiology culture thresholdMicrobiology laboratory culture thresholds commonly use 1 x 10^5 CFU/g (≈10^5 CFU/g) to define clinically significant bacterial load.

Clinical implicationFluorescence imaging may identify bacterial loads below common culture thresholds, potentially flagging pre-infection states for earlier assessment.

Bacterial load threshold used in studies

Study threshold usedStudies evaluating fluorescence imaging report bacterial-load analyses using a threshold greater than 1 x 10^4 CFU/g (>10^4 CFU/g).

Range assessed in trials

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization and Documentation Requirements

Applicable procedure and HCPCS/CPT codes are listed for reference and may be subject to prior authorization or medical necessity review per the member's benefit plan. Listing of a code in this policy does not imply coverage. Providers should document the specific procedure code(s), anatomic site(s), clinical indication, and relevant diagnostic findings in the medical record to support any request for coverage or payment.

Applicable codes include: 0598T, 0599T, 97610, A6000, E0231, E0232 — inclusion does not imply coverage; check plan-specific prior authorization rules.
Prior authorization may be required for ultrasound therapies (e.g., 97610) depending on plan; when required, submit documentation showing prior standard care (compression, offloading, debridement, infection/ischemia control) and rationale for adjunctive ultrasound.
For noncontact fluorescence wound imaging codes (0598T, 0599T), policies may subject these to prior authorization or medical necessity review; provide clinical signs/symptoms assessment (CSS), device findings, and how imaging will change management.
Document imaging findings quantitatively when applicable (e.g., fluorescence-positive area in cm2, wound size measurements, overlap with graft loss) and include microbiology or biopsy results if used to guide care.
Coverage decisions are governed by federal, state, and contractual plan requirements; always verify the member's specific benefit plan and prior authorization rules prior to service.

Background and Rationale

Noncontact normothermic wound therapy (NNWT) applies radiant heat and humidification to wounds to increase local blood flow and oxygen. Low-frequency ultrasound (contact and noncontact) aims to cleanse or debride and may stimulate cellular processes to promote healing. Fluorescence imaging (for example, MolecuLight i:X®) uses violet light to detect bacterial autofluorescence in real time to help identify wounds with elevated bacterial loads. Although these mechanisms are plausible, current clinical evidence is insufficient to establish consistent benefit in patient-centered outcomes.

Definitions

NNWT / Warming therapy

DefinitionNoncontact normothermic wound therapy (NNWT) uses a noncontact wound cover and warming unit to apply radiant heat and maintain near‑100% relative humidity to raise wound temperature and increase local blood flow and oxygen.

Primary intentIntended to increase perfusion and oxygenation of the wound microenvironment to promote healing.

Device componentsTypically includes a warming unit, warming card, and noncontact wound cover (HCPCS codes referenced in policy).

Low-frequency ultrasound (NLFU/MIST)

DefinitionLow-frequency ultrasound (NLFU/MIST) refers to low-frequency, noncontact ultrasound delivered via a saline mist (MIST Therapy®) or contact low-frequency ultrasonic debridement to cleanse and stimulate wounds.

Mechanism

Policy Revision History

2026-03-01coding updateLatest

Updated list of applicable CPT codes; revised descriptions for CPT codes 0598T and 0599T, and archived previous policy version CS132NE.P.

Policy Summary

PayerUnitedHealthcare

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (for Nebraska Only)

Policy CodePolicy CS132NE.Q

Change TypeAnnual coding update

Effective DateMar 1, 2026

Next Review DateN/A

SourceLink

On This Page

Analyses in DFU and other wound studies considered loads across 10^4 to 10^9 CFU/g when comparing clinical assessment to fluorescence imaging.

Relevance to CIBL conceptThe >10^4 CFU/g threshold underpins the chronic inhibitory bacterial load (CIBL) concept referenced as potentially clinically important for earlier intervention.

Denial Risk

Denial Risk for Unproven or Unsupported Services

Claims for noncontact wound-warming therapy (NNWT), low-frequency ultrasound therapy, and real-time fluorescence wound imaging for bacterial presence may be denied as not medically necessary when documentation does not support clinical benefit or plan criteria. Use of device findings alone without corroborating clinical assessment and outcome-oriented rationale increases denial risk.

Denial risk is higher when: documentation lacks evidence of prior standard care, lacks clinical signs/symptoms assessment, or does not show how the service altered management or improved outcomes.
For fluorescence imaging, insufficient evidence that use improves patient-centered outcomes may trigger denials if not tied to a clear clinical plan (e.g., targeted debridement, change in antimicrobial therapy, graft planning).

Documentation Required

Required Clinical Assessment and Imaging Documentation

When using bacterial fluorescence imaging or adjunctive ultrasound, clinical documentation should include a structured assessment of signs and symptoms, device findings, and planned management changes. Record the standard care elements that were tried and the indication for the adjunctive technology.

Include a clinical signs and symptoms (CSS) assessment (NERDS/STONEES or IWII checklist) and note any prior treatments (offloading, compression, debridement, dressings, antibiotic therapy).
When fluorescence imaging is performed, document anatomic site(s), images obtained, description of fluorescence-positive regions (location, cm2), and how findings will guide treatment (e.g., targeted debridement, sampling sites for culture, graft site selection).
For ultrasound therapies, document frequency/duration of therapy, concurrent standard care provided, objective wound measurements (area, percent area reduction), and any adverse events.
Retain and make available stored images and measurement records to support medical necessity and prior authorization appeals.

Billing Rule

Coding and Billing Notes

Follow plan- and code-based authorization workflows and verify coding descriptors prior to claim submission. Updated CPT descriptions for 0598T and 0599T are effective 03/01/2026 — confirm the current code descriptors in the practice management system.

Providers should confirm whether services require prior authorization under the member's benefit plan before providing care.
Ensure submitted claims list the primary procedure code and any additional anatomic site code (e.g., 0598T and 0599T) with supporting documentation.
Inclusion of codes here is for reference only; check payer systems for the most current code lists and coverage statuses.

Note

Plan Requirements and Instructions for Use

When determining coverage and prior authorization requirements, the federal, state, and contractual requirements for the specific benefit plan govern. This policy is informational and does not substitute for plan-specific rules.

Before rendering services, verify member eligibility, benefit coverage, and any plan-specific medical policy or prior authorization requirements.
In the event of a conflict between this policy and a member's contractual requirements, the contractual requirements prevail.

Uses an ultrasonic transducer producing ~40 kHz waves carried in a saline mist to remove slough, exudate, and bacteria and to stimulate cellular processes.

Typical deliveryHandheld transducer held ~1 cm from wound with sterile saline reservoir; single‑use applicator components described by manufacturer.

Fluorescence wound imaging

Device descriptionHandheld fluorescence imaging device using violet light illumination to detect bacterial autofluorescence in real time (example: MolecuLight i:X®).

Intended useProvides clinicians with images documenting presence and location of bacteria to assist diagnostic and treatment decisions at point-of-care.

Limitations notedEvidence is inconclusive that use improves patient-centered outcomes; recommended to be used alongside clinical assessment rather than as sole basis for therapy.

Chronic inhibitory bacterial load (CIBL)

Definition: CIBLChronic inhibitory bacterial load (CIBL) is the concept of a bacterial burden (e.g., ≥10^4 CFU/g) at which bacterial presence may inhibit wound healing and warrant earlier intervention.

Role in studiesCIBL underlies analyses that fluorescence imaging can detect bacterial loads below conventional culture thresholds and may inform earlier management.

Clinical considerationCIBL is a proposed paradigm to encourage intervention along the bacterial–infection continuum but requires outcome evidence for routine use.

Fluorescence imaging metrics

Common metrics reportedSensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy are reported in fluorescence imaging studies.

Example performanceIn a burn graft study fluorescence imaging had sensitivity 86%, specificity 98%, PPV 72%, NPV 99%, and accuracy 94% for predicting graft loss.

Biofilm detection accuracyIn a SEM‑validated trial fluorescence imaging showed sensitivity ~84% and higher accuracy than clinical signs or blotting for biofilm detection.

Clinical criteria sets (NERDS/STONEES)

NERDS/STONEESNERDS (non-healing, exudate, red and bleeding surface or granulation tissue, debris and smell) and STONEES (size, temperature, osteomyelitis, new areas, exudate, erythema, and smell) are clinical criteria sets used to assess wound infection and presence of moderate-to-heavy bacterial loads.

Use with imagingStudies combined NERDS/STONEES (CSS) with fluorescence imaging and reported 2.5–3.2‑fold improvements in diagnostic accuracy versus CSS alone in a small pilot.

DocumentationWhen using fluorescence imaging to guide management, documentation should include CSS assessment (NERDS/STONEES or IWII checklist) correlated with fluorescence findings.

MolecuLight i:X — device summary

Device identityMolecuLight i:X is a handheld fluorescence imaging device intended to identify wounds with elevated bacterial loads by autofluorescence and to document findings in real time.

Clinical evidence noteECRI assessment concludes the evidence is inconclusive for improvement in patient‑centered outcomes; recommended use in combination with clinical assessment.

Study scaleLarge prospective observational study using MolecuLight i:X included 350 participants showing CSS alone missed ~85% of bacterial loads >10^4 CFU/g.

noncontact low-frequency ultrasound

DefinitionNoncontact low-frequency ultrasound refers to ultrasound therapy delivered without contact (e.g., MIST Therapy®), producing a saline mist that carries low‑frequency ultrasonic energy to the wound.

PurposeIntended to cleanse/debride the wound surface, remove slough/exudate/bacteria, and potentially stimulate healing processes.

Evidence summarySystematic reviews and randomized trials report mixed results; larger, well‑designed RCTs are needed to establish clinical utility.

bacterial fluorescence imaging

DefinitionBacterial fluorescence imaging is a real‑time point‑of‑care imaging technique using violet light to visualize bacterial autofluorescence and identify wounds with moderate‑to‑heavy bacterial burden.

Intended clinical roleAdjunct to clinical assessment to localize high bacterial load regions for targeted debridement, sampling, or antimicrobial stewardship.

Evidence limitationsAlthough diagnostic accuracy for detecting high loads is higher than CSS alone, evidence that imaging improves patient‑centered outcomes is insufficient.

local warming therapy

DefinitionLocal warming therapy denotes thermal therapy applied to chronic wounds (e.g., NNWT) intended to increase local perfusion and aid healing.

MechanismApplies radiant heat and humidification to raise wound temperature and increase blood flow and oxygen delivery.

Evidence summarySystematic reviews and small trials yield inconclusive evidence for routine clinical benefit in chronic wounds.